Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II
Source: View publication →
The EVEREST II trial demonstrated that while percutaneous mitral valve repair with the MitraClip system is safer in the short term, it is less effective than conventional surgery at reducing mitral regurgitation, resulting in a higher rate of subsequent surgical intervention.
Key Findings
Study Design
Study Limitations
Clinical Significance
The EVEREST II trial established the MitraClip as a viable, safer, but less anatomically definitive alternative to open mitral valve surgery for select patients, eventually leading to its adoption as a standard therapy for patients with severe degenerative mitral regurgitation who are at prohibitive surgical risk.
Historical Context
As the first randomized controlled trial comparing a percutaneous mitral valve repair device to the gold standard of open-heart surgery, EVEREST II was a landmark study that provided the foundational evidence for transcatheter edge-to-edge repair (TEER) in clinical practice.
Guided Discussion
High-yield insights from every perspective
How does the MitraClip system mechanically replicate the surgical 'Alfieri stitch' to reduce mitral regurgitation, and what is the resulting anatomical configuration of the valve?
Key Response
The MitraClip mimics the Alfieri edge-to-edge repair by grasping the middle portions of the anterior and posterior mitral valve leaflets. This creates a 'double-orifice' mitral valve during diastole, which reduces the regurgitant orifice area during systole by preventing the leaflets from pulling apart.
The EVEREST II 5-year data shows a significantly higher rate of surgery for mitral valve dysfunction in the percutaneous group compared to the surgical group. In clinical practice, how should this influence the counseling of a 55-year-old patient with symptomatic degenerative mitral regurgitation and low surgical risk?
Key Response
For low-risk patients with degenerative MR, surgery remains the gold standard because EVEREST II demonstrated that it is more effective at durable MR reduction. While the percutaneous approach is safer in the immediate 30-day period, the 5-year need for subsequent surgery was 27.9% for MitraClip vs 8.9% for surgery, making surgery the preferred recommendation for those who can tolerate it.
Contrast the long-term durability findings of EVEREST II in primary (degenerative) MR with the outcomes of the COAPT trial in secondary (functional) MR. Why might the 'efficacy gap' between percutaneous repair and surgery be perceived differently in these two populations?
Key Response
In primary MR (EVEREST II), surgery is a curative procedure with high durability, making the clip's lower efficacy a significant drawback. In secondary MR (COAPT), the disease is the left ventricle, not the valve; therefore, even an 'imperfect' MR reduction by a clip provides a profound mortality and hospitalization benefit compared to medical therapy, often making TEER the preferred strategy regardless of whether it matches surgical 'perfection'.
Looking at the 5-year landmark analysis of EVEREST II, once the 6-month 'failure' window has passed, how does the stability of MR reduction in successful MitraClip patients compare to that of surgical patients?
Key Response
The data reveals a 'catch-up' phenomenon: while more clip patients failed early (requiring surgery within 6 months), those who had a successful result at 1 year showed a rate of MR stability (freedom from 3+ or 4+ MR) between years 1 and 5 that was comparable to the surgical group. This suggests that if the clip achieves an early successful result, the repair is remarkably durable over the long term.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The EVEREST II trial utilized a composite primary endpoint including death, surgery for mitral valve dysfunction, and grade 3+ or 4+ MR. Critically evaluate how the different 'failure' mechanisms for each arm (safety events in surgery vs. efficacy events in percutaneous repair) complicate the interpretation of a composite endpoint in a non-inferiority design.
Key Response
Composite endpoints assume all components are of equal clinical weight, but 'need for surgery' (efficacy) and '30-day mortality' (safety) are fundamentally different. The trial showed that surgery's failure was driven by early safety events, whereas MitraClip's failure was driven by late MR recurrence. This creates a 'crossing of the curves' that a single composite value at a specific time point may fail to capture accurately without a formal competing risk analysis.
As a reviewer, how would you address the high rate of crossover (approximately 20%) from the percutaneous group to the surgical group within the first year of EVEREST II, and what impact does this have on the validity of the 5-year Intention-to-Treat (ITT) results?
Key Response
High crossover rates in an ITT analysis typically bias the results toward the null (making the two groups look more similar). Because many 'percutaneous' patients actually received surgical repairs after early clip failure, the long-term ITT results likely overestimate the benefit of the clip-only strategy, necessitating a rigorous per-protocol or as-treated analysis to see the true device performance.
Given the 5-year EVEREST II results, current ACC/AHA guidelines maintain a Class 1 recommendation for surgery in symptomatic patients with degenerative MR. Under what specific conditions do the guidelines elevate percutaneous edge-to-edge repair (TEER) to a Class 2a recommendation for primary MR, and how does EVEREST II support this?
Key Response
Per the 2020 ACC/AHA guidelines, TEER is Class 2a for patients with severe primary MR who are at 'prohibitive risk' for surgery and have favorable anatomy. EVEREST II supports this by showing that despite lower efficacy, the percutaneous approach has superior 30-day safety (fewer major adverse events), making it a viable alternative when the risks of sternotomy and bypass outweigh the benefits of a more durable surgical repair.
Clinical Landscape
Noteworthy Related Trials
COAPT Trial
Tested
Transcatheter edge-to-edge repair (MitraClip)
Population
Patients with symptomatic heart failure and moderate-to-severe secondary mitral regurgitation
Comparator
Guideline-directed medical therapy alone
Endpoint
Hospitalization for heart failure within 24 months
MITRA-FR Trial
Tested
Transcatheter edge-to-edge repair (MitraClip)
Population
Patients with severe secondary mitral regurgitation and left ventricular systolic dysfunction
Comparator
Guideline-directed medical therapy
Endpoint
All-cause death or unplanned hospitalization for heart failure at 12 months
RESHAPE-HF2 Trial
Tested
Transcatheter edge-to-edge repair (MitraClip)
Population
Patients with heart failure and moderate-to-severe secondary mitral regurgitation
Comparator
Guideline-directed medical therapy alone
Endpoint
Cardiovascular death or heart failure hospitalization
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis